NCT02965885 - A Study of TAS-116 in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

May 3, 2019

Study Completion Date

May 3, 2019

Conditions

Advanced Solid Tumors

Interventions

DRUG

TAS-116

TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.

Trial Locations (12)

20141

Istituto Europeo di Oncologia , Sviluppo di Nuovi Farmaci per Terapie Innovative, Milan

29605

Greenville Health System, Institute for Translational Oncology Research, Greenville

40138

Policlinico S.Orsola-Malpighi, U.O. Oncologia Medica, Bologna

44106

University Hospitals Case Medical Center, Cleveland

86885

US Oncology - Virginia Cancer Specialists, P.C., Fairfax

95123

Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele Oncologia Medica, Catania

00144

Regina Elena National Cancer Institute, Roma

Unknown

Northern Centre for Cancer Care, Newcastle upon Tyne

SE19 9RT

Division of Cancer Studies, Kings College London, London

W1G 6AD

Sarah Cannon Research Institute UK, London

M20 4BX

The Christie NHS Foundation Trust Institute of Cancer Sciences, University of Manchester, Manchester

SM2 5PTT

Royal Marsden, Sutton

All Listed Sponsors

lead

Taiho Oncology, Inc.

INDUSTRY